| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.3 | 3.1 |
| Profit before tax | -5.8 | -9.6 |
| Net income | -5.8 | -9.6 |
| EPS (diluted, $ a share) | $-9.23 | $-2,032.95 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -24.0% |
|---|---|
| Operating margin | -257.1% |
10-Q filed with the SEC, NASDAQ: JAGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Jaguar Health, Inc.: key numbers
- Share price
- $0.3799Close, Nov 17
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Jaguar Health, Inc.
All →Jaguar Health Financial Results
Jaguar Health reported its third quarter 2026 financial results, highlighting a significant $10.1 million reduction in outstanding debt. The company is transitioning to a distribution and R&D model following its U.S. commercial licensing agreement with Woodward Specialty, focusing on its rare disease intestinal failure program for crofelemer.
Jaguar Health Shareholder Meeting
Jaguar Health held a special meeting of stockholders on November 6, 2026, where all six submitted proposals were approved. Key approvals included the issuance of common stock upon exchange of Series Q Preferred Stock and debt, the repricing of investor warrants to $1.00 per share, an increase in authorized shares for the 2014 Stock Incentive Plan, and the authorization for a potential reverse stock split at a ratio between 1-for-2 and 1-for-150.
Jaguar Health Other 8-K Filing
Jaguar Health announced the automatic conversion of its Series R Convertible Preferred Stock into common stock on November 2, 2026. Each share of Series R Preferred Stock, which was previously issued as a special dividend, converted into five shares of common stock, resulting in a total of 13,345,986 shares of common stock outstanding.
Jaguar Health Stock Plan Amendment
Jaguar Health filed a proxy supplement regarding Proposal 3 for its upcoming special meeting, seeking shareholder approval to increase the 2014 Stock Incentive Plan's authorized shares to 378,859. This share reserve represents 14% of the company's issued and outstanding common stock on a fully diluted basis as of September 30, 2026. The supplement clarifies the share count following a special one-time dividend of Series R Preferred Stock and its subsequent conversion into common stock.
Jaguar Health Dividend
Jaguar Health has declared a special stock dividend of Series R Convertible Preferred Stock to common stockholders and certain warrant holders of record as of October 13, 2026. Each share of the new preferred stock is scheduled to convert into five shares of common stock on November 2, 2026, a move intended to provide dilution protection to existing shareholders. Additionally, the company amended existing royalty interests and a promissory note to extend payment and maturity dates to January 1, 2027.
Jaguar Health $3.4M Debt Financing with Streeterville Capital, LLC
Jaguar Health entered into exchange agreements with Streeterville Capital to reduce the outstanding balance of a 2021 secured promissory note by $3.4 million. In exchange for this debt reduction, the company issued 481,584 shares of its common stock to the lender. The transaction was conducted as a privately negotiated exchange exempt from registration under Section 3(a)(9) of the Securities Act.
- Value
- $3.4M
- Counterparty
- Streeterville Capital, LLC